Reactive oxygen species activated by mitochondria-specific camptothecin prodrug for enhanced chemotherapy


  • Zhaopei Guo State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China; Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China
  • Zian Wang State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China
  • Ruifeng Liang State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China
  • Huayu Tian Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China
  • Xuesi Chen Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China
  • Meiwan Chen State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China



Camptothecin prodrug, reactive oxygen species, antitumor therapy


Camptothecin (CPT) has attracted much attention due to its potent antitumor activities. However, the undesirable physicochemical properties, including poor water-solubility, unstable lactone ring and severe adverse effects limit its further application. In this study, two water-soluble prodrugs, CPT-lysine (CPTK) and CPT-arginine (CPTR), were designed and synthesized by conjugating lysine or arginine with CPT, improving its solubility, pharmacokinetic properties and tumor penetration. Importantly, the introduction of arginine into CPTR contributed to the mitochondria-specific delivery, which increased mitochondrial reactive oxygen species (ROS) generation, induced mitochondria dysfunction and enhanced cell apoptosis and in vivo anti-cancer effect. This strategy is believed to hold great potential for organelle-specific synergistic anti-tumor therapy.


Download data is not yet available.
Reactive oxygen species activated by mitochondria-specific camptothecin prodrug for enhanced chemotherapy


Additional Files



How to Cite

Guo Z, Wang Z, Liang R, Tian H, Chen X, Chen M. Reactive oxygen species activated by mitochondria-specific camptothecin prodrug for enhanced chemotherapy. Biomol Biomed [Internet]. 2022Oct.23 [cited 2023Sep.28];22(6):934-48. Available from:





Camptothecin (CPT), first isolated from the Chinese tree Camptotheca acuminata, was widely used in preclinical or clinical anti-cancer therapy, including lung, colon, and breast cancer, as the topoisomerase I inhibitor [1,2]. However, poor water solubility and the instability of lactone ring in the physiological environment limit the therapy efficacy of CPT [3-5]. Another bottleneck in the application of CPT is the high-dose requirement and systemic toxicity due to its non-specificity. Tumor-specific delivery, including delivery to tumor tissues, tumor microenvironment, cells, and subcellular organelles (mitochondria, lysosome, endoplasmic reticulum, etc.), has gained much attention and exhibits great potential for therapeutic efficacy improve [6].

Among them, mitochondria, as the major cellular powerhouse, plays an essential role in cancer cell survival, as well as cell invasion and metastasis. Therefore, this organelle has attracted wide attention in cancer therapy [7,8]. Mitochondrion showed different functions in cancer cells compared to normal cells, including different metabolic activity, reactive oxygen species (ROS) generation, and transmembrane potential [9-12]. Mitochondria are the main source of superoxide radicals, which provide the possibility of exceeding cytotoxic thresholds in cancer cells [13,14]. Therefore, the development of novel mitochondrial-targeted CPT derivatives and CPT-based drug delivery systems would contribute to the powerful cancer therapy based on improved drug stability, efficient drug delivery, mitochondrial disruption, and associated homeostasis imbalance.

At present, various mitochondria-targeted nanosystems are developed for improved cancer therapy [15-17]. The molecules containing positive charges were regarded as an efficient tactic in traversing mitochondria double membrane to achieve mitochondria-targeted delivery. For example, triphenylphosphonium bromide was used as a classical mitochondria-targeting agent [18]. Nevertheless, the extremely low loading efficiency and instability of CPT hindered its further applications [19]. Amino acids (lysine, glycine, arginine, etc.) as promoieties have drawn much attention as well, since they provide structural diversity and expanse of physicochemical properties for optimization in drug delivery [20,21].

For instance, Vale et al. designed and synthesized new bromothiazole derivatives with amino acids, and confirmed the antiproliferative activities against colon cancer cells [22]. Deshmukh’s team confirmed that the introduction of amino acids (aminobutyric acid and norvaline) to CPT was able to stabilize the lactone form and offer the platform for further drug delivery [23]. Etienne et al. synthesized a series of CPT-amino acids carbamate linkers with a convenient and facile approach, in which the intramolecular cyclization contributed to increased stability and drug potency [21]. Azzolini et al. used carbamate ester as a linker to introduce isoleucine, to increase absorption, reduce metabolism, and acquire higher drug concentrations of pterostilbene [24]. Among these amino acids, the positively charged amino acid arginine holds great potential in the design of both cell-penetrating and mitochondrial-targeted drug delivery systems [25]. On the other hand, the amphiphilicity of water-soluble amino acid-modified CPT prodrugs is beneficial for the construction of carrier-free drug delivery nanosystems (nanospheres, nanotubes, nanofibers, or nanowires) with high CPT loading content based on self-assembly of drugs [26]. For example, π-π stacking between the heterodimeric prodrugs 7-ethyl-10-hydroxycamptothecin (SN38) and taxane largely increased the stability of heterodimeric prodrugs and lipid carrier-based micelles, as well as the drug loading content [27].

As shown in Scheme 1, positively charged amino acid-modified CPT prodrugs were synthesized (CPTK and CPTR) and assembled into nanoparticles to achieve improved cancer therapy based on increased drug stability, mitochondrial-targeted delivery, and deeper tumor penetration, with the following advantages exhibited. First, the improved water solubility and stability of CPTK and CPTR provided significant advantages over CPT for in vivo applications. Second, CPTR elevated ROS levels based on efficient drug penetration in mitochondria and induced mitochondria dysfunction. In addition, CPTR exhibited powerful penetration ability, contributing to in vivo cancer therapy. Thus, the novel CPT derivatives were supposed to have great potential in clinical anti-cancer therapy.

SCHEME 1: Schematic illustration of the anticancer mechanism of CPT prodrugs. CPT: camptothecin.



Boc-Arg (Pbf)-OH and Boc-Lys (Boc)-OH were purchased from GL Biochem Ltd. (Shanghai, China). CPT was purchased from Dalian Meilun Biotechnology Co., Ltd. (Dalian, China). Trifluoroacetic acid (TFA) was obtained from Xiya Reagent Co., Ltd. (Linyi, China). EDC hydrochloride was provided by J&K Scientific Ltd. (Beijing, China). N-Hydroxysuccinimide and DMAP were supplied by Aladdin Co. Ltd. (Shanghai, China). 4’-6-diamidino-2-phenylindole was purchased from Sigma-Aldrich (St. Louis, MO, USA). Methyl thiazolyl tetrazolium (MTT) was obtained from Amresco (Solon, Ohio, USA). Annexin V-FITC apoptosis detection kit, ROS Assay Kit (DCFH-DA), Mitochondrial Membrane Potential Assay Kit with Rhodamine 123, Fluo-4 AM, and MitoTracker Red were obtained from Beyotime (Shanghai, China). Fluorescein isothiocyanate (FITC) was obtained from Dingguo Biotechnology Company (Beijing, China).

Characterization of CPTR and CPTK

The fluorescence spectrum of CPTR and CPTK (50 μM in 10 mM PBS) was measured using a fluorometer (Photon Technology International Inc., Canada) at 0 hour, 24 hours, and 48 hours after being dissolved in PBS. CPTR and CPTK were dissolved in water or DMSO (10 μM). Then, the UV-Vis-NIR spectra were obtained by spectrophotometer (U-4100, Hitachi, Japan).

Characterization of prodrug-based nanoparticles

To prepare prodrug-based nanoparticles, CPTK and CPTR were dissolved in the deionized water or 10% FBS solution (0.125, 0.25, 0.5, and 1.0 mg/mL), which would self-assemble into nanoparticles based on their amphiphilic structure. The size distribution and zeta potential were measured by Malvern Zetasizer Nano-ZS90 (Malvern Instruments, Malvern, UK) based on dynamic light scattering (DLS) method. The morphology was observed by scanning electron microscopy (SEM, Merlin, Zeiss, Germany).

Cell lines

HeLa, MCF7, B16F10, 4T1, and CT26 cells were obtained from American Type Culture Collection, Rockville, USA, and cultured in DMEM with 10% (v/v) heat-inactivated FBS, 100 mg/mL streptomycin, and 100 units/mL penicillin in an incubator (37°C, 5% CO2, 95% humidity).

Flow cytometry

CPTR and CPTK were labeled with FITC for cell uptake analysis. CPTR (100 mg) and FITC were dissolved in 30 mL of deionized water with a molar ratio of 1.2:1, and the reaction was conducted at room temperature for 24 hours. Subsequently, insoluble solids in the water were removed by centrifugation (8000 rpm) after sonication. CPTK-FITC was synthesized with similar methods (CPTK: 100 mg). CT26 cells were cultured in 6-well plates at a density of 1.0 × 105 cells per well. After incubation at 37°C for 24 hours, cells were treated with different formulations with equivalent CPT concentration (5 μM), respectively, and then cultured for another 6 hours. The control group was treated with an equal volume of serum-supplemented culture medium without drug. Then, cells were washed with PBS and analyzed through flow cytometry (FACS Caliber, Becton-Dickinson, San Jose, CA, USA).

Confocal laser scanning microscopy (CLSM)

CT26 cells were seeded on the coverslips in 6-well plates with a density of 1.0 × 105 cells per well and cultured for 24 hours, then CPT, CPTK, and CPTR were added at a concentration of 5 μM. After 6 hours incubation, cells were treated with MitoTracker Red for another 30 minutes at 37°C, then washed and fixed with 3.7% paraformaldehyde, followed by observation using a CLSM, Leica TCS SP2; Leica Microsystems, Wetzlar, Germany.

Cytotoxicity assay

MTT assay was employed to assess the cytotoxicity of CPT, CPTK, and CPTR against different cell lines, including HeLa, 4T1, B16F10, and CT26 cells. Briefly, cells were seeded at a density of 1.0 × 104 cells per well in 96-well plates and incubated for 24 hours. Then, the culture medium was replaced with a medium containing different concentrations of CPT, CPTK, and CPTR. The CPTK and CPTR were dissolved in saline before use. CPT was first dissolved in DMSO and then diluted in a culture medium. After another 48 hours, 20 μL of MTT (5 mg/mL) was added to each well and the cells were incubated for another 4 hours. Then, MTT-containing solution was removed and 200 μL of DMSO was added to dissolve the MTT formazan crystals. Finally, the absorbance at 490 nm of each well was recorded by an ELISA microplate reader (Bio-Rad, USA). The cell viability (%) was calculated according to the following equation:

Cell viability (%) = (Asample/Acontrol) × 100%

Where, Asample and Acontrol represented the absorbance in the drug-treated groups and control group, respectively. Data were shown as mean ± SD based on triplicate independent experiments.

Cell apoptosis assay

CT26 cells were cultured in 6-well plates with a density of 1.0 × 105 cells per well and cultured for 24 hours. Then, CPT, CPTK, and CPTR were added with a final concentration of 5 μM. After 24 hours incubation, the apoptotic cells were treated with the Annexin V-FITC apoptosis detection kit according to the manufacturer’s instructions (BD Biosciences, San Jose, USA) and the results were analyzed by flow cytometry.

Intracellular ROS detection

The ROS generation was accessed by ROS Assay Kit (DCFH-DA) in different cell lines, including 4T1, B16F10, HeLa, and CT26 cells. Briefly, cells were seeded at a density of 1.0 × 104 cells per well in 24-well plates and incubated for 24 hours. Then, the culture medium for each well was replaced with 500 μL of DMEM containing CPT, CPTK, and CPTR at a final drug concentration of 5 μM. After 6 hours incubation, cells were treated with the ROS fluorescent probe (10 mM) for 20 minutes and washed thrice with PBS for CLSM observation.

Mitochondrial potential assessment

CT26 cells were seeded on 24-well plates at a density of 1.0 × 104 cells per well and treated with 5 μM of CPT, CPTK, and CPTR for 2 hours, respectively. Subsequently, the cells were cocultured with rhodamine 123 for 30 minutes. Then, the cells were washed with PBS and observed with a fluorescence microscope and analyzed by flow cytometry.

Intracellular Ca2+ detection

The Fluo-4 AM probe was applied to access the intracellular Ca2+ concentration. Briefly, CT26 cells were seeded on 24-well plates at a density of 1.0 × 104 cells per well and treated with 5 μM of CPT, CPTK, and CPTR for 24 hours, respectively. After being washed with fresh mediums, the cells in different groups were incubated with Fluo-4 AM for 20 minutes and evaluated with flow cytometry.

3D spheroid model (3DSM) for in vitro tumor penetration

CT26 cells were seeded in low attachment 24-well plates at a density of about 4.0 × 104 cells per well and incubated at 37°C for 5 days. Then, CPT, CPTK, and CPTR were added into the media with the final CPT concentration of 10 μg/mL and incubated for another 2 or 24 hours. Then, the 3DSMs were washed by PBS thrice and put onto a glass slide for CLSM observation.


Female BALB/C mice (4-5 weeks) were bought from Vital River Company (Beijing, China). The normal mice were injected with CPT, CPTK, and CPTR at an equivalent CPT dose of 1 mg/kg through tail vein. At different time intervals (0.5, 1, 2, 4, 6, 8, 12, and 24 hours), the blood samples were collected through tail vein using sodium-heparinized micropipettes, transferred to heparinized blood collecting tubes, and stored at −80°C for further analysis. Then, 20 μL of blood was transferred to a black 96-well plate and diluted to 200 μL by PBS. Furthermore, CPT fluorescence was measured on a Tecan infinite M200 Microplate Readers (Tecan, Austria) at λex = 370 nm and λem = 435 nm, and the fluorescence intensity of untreated groups was used as a negative control. The acquired values were normalized to CPT concentration which was calculated based on the naked CPT calibration curves.

In vivo tumor treatment and histological analysis

CT26 cells suspended in PBS were subcutaneously injected into BALB/C mice to establish CT26 tumor-bearing models for investigation of in vivo antitumor efficacy. When the tumor size became approximately 150 mm3, the tumor-bearing mice were divided randomly into six groups and administered with PBS, CPTK, and CPTR through intravenous or intraperitoneal (for CPT) injection every 3 days, with a total 5 times injection (10 mg/Kg of CPT). The CPTK and CPTR were dissolved in saline before use in vivo. CPT was first dissolved in DMSO and then diluted in normal saline. The tumor size and body weight were measured every other day. Tumor volume (V) was calculated as follows: V = 0.5 ab2, where a and b represented the longest (a, mm) and the shortest (b, mm) diameters of tumor measured by a Vernier caliper. After treatment, the heart, liver, lung, spleen, kidney, and tumor were dissected from the mice for histopathological analysis. The tissues were paraffin embedded and sliced at 5 mm thickness. Then, the tissue slices were stained with hematoxylin and eosin (H&E) to assess histological alterations with a microscope.

Ethical statement

All animal experiments were performed under the Guidelines for Care and Use of Laboratory Animals of Northeast Normal University and approved by the Animal Ethics Committee of Northeast Normal University.

Statistical analysis

All measurements were conducted in triplicate and expressed as mean ± standard deviation. The Student’s t-test or the one-way ANOVA test was performed to compare the statistical significance. *p < 0.05 was considered statistically significant. **p < 0.01 and ***p < 0.001 were considered extremely statistically significant.


Synthesis and characterization of CPTK and CPTR

Water-soluble prodrugs CPTR and CPTK were prepared by the coupling reaction between CPT with Arg or Lys, respectively (Figure S1A). CPTR (percentage yield: ~78.5%) and CPTK (percentage yield: ~87.4%) were characterized by 1H-NMR, and the position of each peak was labeled, as shown in Figure S1. Typically, the peaks from 1.2 ppm to nearly 2 ppm and 4.5 ppm represent that arginine or lysine was successfully conjugated to CPT (Figure S1B). The result of mass spectrometry (Figure S1C) further proved the successful synthesis of CPTR and CPTK.

Characterization of prodrug-based nanoparticles

The introduction of water-soluble amino acids increased the water solubility of CPT. Meanwhile, their positively charged unit was used for mitochondrial-targeted delivery. However, a high concentration of negatively charged proteins existing in the serum will be absorbed on the surface of the nanosystems based on electrostatic adsorption and affects the in vivo fate of nanosystems [28]. Thus, it is necessary to characterize the physicochemical variations of the CPTK/CPTR-based nanosystem after coincubation with negatively charged proteins. For this, CPTK and CPTR were incubated with 10% FBS solution at different drug (CPT) concentrations (0.125-1 mg/mL). As shown in Figure 1, the size of CPTR/FBS was much smaller than that of CPTK/FBS under different drug concentrations. This phenomenon can be attributed to the guanidinium group of arginine, which provides a stronger interaction with aromatic residues in proteins to reduce protein aggregation compared with lysine [29,30]. The zeta potential of CPTR and CPTK in 10% FBS solution was also measured, both showing a sharp decrease after being complexed with FBS (Figure 1B).

FIGURE 1: Characterization of CPTK/FBS and CPTR/FBS. (A) Particle size of CPTK and CPTR with different CPT concentration in FBS (10%); (B) zeta potential; and (C and D) the SEM picture of CPTR/FBS and CPTK/FBS. *** p < 0.001 (Student's t-test).

The closed lactone form of CPT had highly efficient anti-cancer activity, which decreased significantly in the open lactone form. To estimate the lactone stability of CPTR and CPTK, fluorescence emission spectral shift measurements were performed. As displayed in Figure S2A and B, even after the nanosystems were dissolved in PBS for 48 hours, the emission peak was only shifted from 434 nm to 437 nm for CPTR and from 434 nm to 438 nm for CPTK, which indicated that both CPTR and CPTK were mostly remained in closed lactone form with highly efficient anti-cancer activity, rather than open carboxylate with an emission peak at 446 nm [31,32]. MTT assay in A549, B16F10, and CT26 cell lines also confirmed that there was no obvious difference in the anti-cancer ability of CPTR and CPTK after 0, 12, 24, and 48 hours incubation in PBS, which was further proved the high stability of prodrugs (Figure S2C-E).

To study the self-assembly behavior of the prodrug, the UV-Vis spectrum was analyzed to investigate the state of CPTR and CPTK in water and DMSO. Figure S3A shows that CPTK had two obvious absorption peaks at 352 nm and 368 nm in water, and 367 nm and 370 nm in DMSO, respectively, indicating the existence of an aggregated state. Similar properties can also be observed in CPTR (Figure S3B), and the self-assembling process might be attributed to the hydrophobic and π-π stacking interactions based on the π-electronic planar of CPT [33,34].

In vitro cytotoxicity and cell uptake efficiency

The fluorescence spectrum had shown that CPTK and CPTR were able to keep closed lactone for a long time, which was considered an active form of CPT. The anti-cancer ability of CPT, CPTK, and CPTR was measured in HeLa, MCF7, CT26, 4T1, and B16F10 cells (Figure 2). CPTR showed a higher cell proliferation inhibition rate compared with CPT and CPTK. No significant differences in cell viability were found among the three groups. However, the IC50s of CPTR in different cell lines were lower than in the other two formulations, as shown in Table S1. To explore the underlying mechanism, we selected CT26 cells to study the cellular uptake efficiency of CPTK and CPTR. CPTK and CPTR were labeled with FITC. The result showed that CPTK and CPTR had similar cellular uptake, which means that cellular uptake was not the key factor that led to the difference in cell toxicity (Figure 3).

FIGURE 2: In vitro cytotoxicity of CPT, CPTK, and CPTR in different cell lines. (A) HeLa cells; (B) MCF7 cells; (C) CT26 cells; (D) 4T1 cells; and (E) B16F10 cells. Cell viability was evaluated by MTT assay after different treatments for 48 hours.
FIGURE 3: Cellular uptake in CT26 cell, CPTK, and CPTR labeled with FITC (6 hours, 5 μM).

Cell apoptosis, ROS detection, mitochondria CPT colocalization assay, and associated membrane potential assessment

Cell apoptosis assay was further employed to evaluate the anti-cancer activity of CPT, CPTK, and CPTR. At an equivalent drug concentration of 5 μM, an increase in cell apoptosis (41.5%) was found in the CPTR group compared with CPT (34.3%) and CPTK (27.5%) (Figure 4A and B, control group: ~9.35%), which is different from the above results of cellular uptake. Recent studies proved that CPT inhibited mitochondria oxygen consumption and increased ROS generation, which contributed to cell apoptosis [13,14]. The ROS detection was conducted in CT26 cells, as shown in Figure 4C, and the CPTR group exhibited a higher ROS level (green fluorescence signal). Similar results were obtained in other cell lines (Figure S4).

FIGURE 4: Measurement of apoptosis rates of CT26 cells treated with CPT, CPTK, or CPTR and the ROS detection. (A) Flow cytometry analysis of apoptosis (24 hours, 5 μM); (B) apoptosis rate (24 hours, 5 μM); and (C) ROS generation after CPT, CPTR, and CPTK treatment (6 hours, 5 μM). The statistical significance was calculated through one-way ANOVA test. **p < 0.01.

Then, the intracellular fate of CPT, CPTK, and CPTR was explored. As shown in Figure 5, CLSM images revealed that CPTR showed significant mitochondrial colocalization signal despite similar cellular uptake, which confirmed that the efficient anti-cancer ability of CPTR was associated with mitochondria-targeted delivery and subsequent ROS generation, except for the function of topoisomerase I inhibition for CPT.

FIGURE 5: CLSM images of colocalization of mitochondria and CPT (6 hours, 5 μM). Blue color represents CPT, CPTK, or CPTR. Mitochondria were stained with MitoTracker Red (red).

The membrane potential variation was also accessed after 2 hours treatment of CPT, CPTK, and CPTR. As shown in Figures 6A and B, the mitochondrial membrane potential in CPTR decreased significantly when compared with the untreated group. These results verified the prediction that mitochondria-targeted delivery induces significantly mitochondrial dysfunction. Furthermore, mitochondria are involved in intracellular calcium homeostasis regulation, which is attractive for therapeutic intervention [35]. The changes in cellular Ca2+ concentration were accessed due to its important role in tumors [36]. As shown in Figure 6C, Ca2+ in the CPTR group was increased compared with the control group (p < 0.05). Although the calcium concentration in the CPTR group was higher than that in the CPT and CPTK groups, the data were not statistically different. This may be related to the toxicity of CPT itself.

FIGURE 6: Variations in mitochondrial and calcium homeostasis. (A) CLSM images of mitochondrial potential changes (2 hours, 5 μM); (B) flow cytometry analysis of mitochondrial membrane potential changes (2 hours, 5 μM); and (C) evaluation of calcium ion concentration (24 hours, 5 μM). *p < 0.05, ***p < 0.001, ****p < 0.0001 (one-way ANOVA).

In vitro tumor penetration to 3DSM

The in vitro evaluation of tumor penetration ability of CPT, CPTK, and CPTR was carried out using a 3DSM derived from CT26 cells. As shown in Figure 7, CPT was mostly dispersed at the periphery of 3DSM, and the negligible fluorescence signal was detected in the center of 3DSM after 2 hours incubation. By contrast, the fluorescence signals of CPTK and CPTR were detected much deeper inside of 3DSM. After 24 hours coincubation, the stronger fluorescence signals for CPTK and CPTR suggested their higher tumor penetration ability than CPT.

FIGURE 7: In vitro tumor penetration of CPT, CPTK, and CPTR in 3DSMs after 2 or 24 hours of incubation (with the CPT concentration of 10 μg/mL). Scale bar represents 200 μm.

Pharmacokinetics, in vivo tumor treatment, and histological analyses

The blood concentration of CPT at fixed time intervals was further measured to study the pharmacokinetic profiles of different formulations (Figure 8A). Consistent with previous reports, the detected CPT concentration in blood decreased dramatically. However, the decrease in CPT concentration was significantly delayed in CPTK and CPTR groups. The improved blood concentration of CPTK and CPTR may be attributed to the positive charge, which was combined with negatively charged serum proteins after injecting into the blood, thus preventing the formation of large particle embolism inducing mice death.

FIGURE 8: In vivo anti-tumor therapy. (A) CPT concentration in blood versus time after intravenous injection of CPT, CPTK, and CPTR in mice (10 mg/Kg of CPT concentration); (B) tumor volume changes during treatment (0, 3, 6, 9, and 12 were the time point of drug injection); (C) the body weight changes during treatment; (D) tumors were excised from each group after the sacrifice of mice; and (E) H&E staining images of tumor collected from CPTK and CPTR injected mice and control treated mice with PBS. ** p < 0.01 (one-way ANOVA).

Inspired by the in vitro experiments, in vivo anti-cancer evaluation was carried out to further investigate the potential use of CPTK and CPTR. As displayed in Figure 8B and D, the growth rate of tumors was significantly restrained in all treatment groups, and the average tumor size was no larger than 500 mm3. The groups of CPTK and CPTR showed high antitumor efficacy with an average tumor size lower than 150 mm3 after treatment, which was in accordance with the cell apoptosis results. In addition, mice treated with CPT had a sharp decrease in body weight compared to other groups, indicating that CPT had serious side effects on mice when injected directly (Figure 8C).

Further safety evaluation of CPTK and CPTR was analyzed through H&E staining (Figure 8E and Figure S5). Compared with the PBS group, the CPTK and CPTR groups showed obvious cell nuclei dissolution, especially in CPTR groups. H&E-stained tissue sections from the heart, liver, spleen, lung, and kidney demonstrated that the prodrug had no significant damage or toxicity to these organs. According to in vivo antitumor therapy results, CPTR and CPTK showed high efficiency in tumor suppression, which may attribute to their deeper tumor penetration. More importantly, the positively charged units of CPTR and CPTK had little effect on their blood circulation, which is beneficial for further application.


The clinical application of CPT is limited by poor water solubility, undesirable adverse effects, as well as the instability of lactone rings in the physiological environment. Self-assembly nanocarriers based on prodrugs provided a powerful way for elevating therapy efficiency of CPT-based cancer treatment due to many advantages, including high loading capacity, precisely defined chemical structure, and convenient preparation. For example, CPT can be conjugated with polymers [37], amino acids [38], peptides [39], and polysaccharides [40] to form carrier-free nanomedicine. Among them, the introduction of amino acids to CPT has been regarded as a promising method for modification and further application of CPT due to commercial availability, fewer safety issues, and targeting influx transporters, which have been widely applied to improve pharmaceutical properties of marketed drugs [41]. Herein, positively charged amino acids (lysine and arginine) were introduced to synthesized CPTK and CPTR for the construction of CPT-based drug delivery systems with high CPT loading content and increased stability of lactone ring. Studies have shown that the cationic prodrugs CPTK and CPTR can assemble into uniform nanoparticles with the negatively charged proteins in the blood. Meanwhile, both CPTK and CPTR have excellent lactone stability even after 48 hours, which enjoy highly efficient anti-cancer activity when compared with opened carboxylate form.

In addition to the increased water solubility and stability, due to the positive charge of lysine and arginine, the nanosystems achieved the mitochondrial-targeted delivery of CPT. Since CPT can inhibit mitochondrial oxygen consumption, which leads to elevated ROS levels and final cell apoptosis, the targeted delivery of CPT would contribute to enhanced cancer cells inhibition. Although CPTK and CPTR exhibited similar cellular uptake, CPTR induced more cell apoptosis, which was associated with its better mitochondrial targeting ability. It could be inferred that the topoisomerase I inhibition, the elevated ROS level, and calcium ion concentration contribute to more effective cancer cells inhibition. Upregulation of intracellular calcium concentration to disrupt mitochondrial calcium homeostasis has been recognized as a potential cancer therapy [42].

However, as an important regulator of intracellular homeostasis, mitochondrial changes can also adversely affect intracellular calcium ion concentration. CPTR effectively increases cellular ROS levels by targeting mitochondria, which would stimulate the release of calcium ions from the endoplasmic reticulum [43-45]. Furthermore, the modification of amino acids provides higher tumor penetration ability, which makes CPTK and CPTR show higher cancer suppression ability than CPT. Meanwhile, the side effects of CPTK and CPTR were significantly reduced when compared with free CPT. Free CPT has significant toxic effects due to systemic delivery and the limited therapy efficiency associated with the unstable lactone ring [46].

CPTK and CPTR self-assemble into nanoparticles in the physiological environment, which can passively target tumors. In vitro experiments showed that CPTK and CPTR had higher lactone ring stability and fully penetrated tumors when compared with free CPT, which enabled them to effectively inhibit tumor progression with reduced systemic toxicity. Therefore, the introduction of amino acid-modified CPT prodrugs can make up for the shortcomings of current CPT drugs and promote their clinical applications. In cell experiments, it is interesting that an elevated MitoTracker fluorescence level was observed in the CPTR group, which could be associated with mitochondrial biogenesis. Possible reasons involve complex regulation to maintain intracellular homeostasis. On the one hand, oxidative stress-induced mitochondrial damage may activate cellular self-regulation to protect mitochondrial integrity and quality [47]. In this process, cells promote autophagy of damaged mitochondria and stimulate healthy mitochondria to proliferate through mitochondrial biogenesis [48,49]. On the other hand, ROS production induces endoplasmic reticulum stress and subsequent calcium release, which disrupts calcium homeostasis and activates mitochondrial biogenesis [43,44,50]. Since mitochondrial biogenesis plays an important role in tumorigenesis and escape, mitochondrial biogenesis should be considered to optimize therapeutic efficacy in future studies.


In this work, CPTK and CPTR were developed and successfully synthesized to improve both the water solubility and stability of CPT. CPTK and CPTR were also proved to be in closed lactone form, even when dissolved in PBS for 48 hours, which was crucial for keeping their anti-cancer activity. Importantly, CPTR exhibited a significantly higher ability to induce cell apoptosis than CPT and CPTK based on its mitochondria-targeted delivery to increase ROS generation. The in vivo anti-cancer results showed that CPTR had a higher tumor-suppressive effect than other groups. Meanwhile, none of them caused toxicity in major organs. Therefore, CPTR can be regarded as a promising candidate prodrug of CPT for clinical antitumor treatment.


  1. , , (). On the mechanism of topoisomerase-I inhibition by Camptothecin-evidence for binding to an enzyme DNA complex. Biochemistry.
  2. , , , (). Evaluation of the cytotoxic effect of camptothecin solid lipid nanoparticles on MCF7 cells. Drug Deliv.
  3. , , (). Preparation and characterization of Pluronic/TPGS mixed micelles for solubilization camptothecin. Colloid Surface B.
  4. , (). A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogs. J Pharm Sci.
  5. , (). Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry.
  6. , , , , , (). Current multistage drug delivery systems based on the tumor microenvironment. Theranostics.
  7. , , , (). Mitocans revisited:Mitochondrial targeting as efficient anti-cancer therapy. Int J Mol Sci.
  8. , (). Mitochondria as a therapeutic target for common pathologies. Nat Rev Drug Discov.
  9. , (). Mitochondrial dysfunction in cancer. Mitochondrion.
  10. , , , , (). The effect of mitochondrially targeted anticancer agents on mitochondrial (super) complexes. Methods Mol Biol.
  11. , , (). Targeting cancer cell mitochondria as a therapeutic approach:Recent updates. Future Med Chem.
  12. , , (). Targeting cancer cell mitochondria as a therapeutic approach. Future Med Chem.
  13. , , , , , (). Camptothecin induced mitochondrial dysfunction leading to programmed cell death in unicellular hemoflagellate Leishmania donovani. Cell Death Differ.
  14. , , , (). Mitochondria-specific drug release and reactive oxygen species burst induced by polyprodrug nanoreactors can enhance chemotherapy. Nat Commun.
  15. , , , , , (). Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response. Biomaterials.
  16. , , , , , (). Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1. J Am Chem Soc.
  17. , , , , , (). Strategies to target bioactive molecules to subcellular compartments. Focus on natural compounds. Eur J Med Chem.
  18. , , , , , (). Mitochondria-targeted triphenylphosphonium-based compounds:Syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chem Rev.
  19. , , , , , (). Dimeric drug polymeric nanoparticles with exceptionally high drug loading and quantitative loading efficiency. J Am Chem Soc.
  20. , , , (). Amino acids as promoieties in prodrug design and development. Adv Drug Deliv Rev.
  21. , , , (). Synthesis of camptothecin-amino acid carbamate linkers. Amino Acids.
  22. , , , , (). In vitro studies on the inhibition of colon cancer by amino acid derivatives of bromothiazole. Bioorg Med Chem Lett.
  23. , , , , (). A series of alpha-amino acid ester prodrugs of camptothecin:In vitro hydrolysis and A549 human lung carcinoma cell cytotoxicity. J Med Chem.
  24. , , , , , (). New natural amino acid-bearing prodrugs boost pterostilbene's oral pharmacokinetic and distribution profile. Eur J Pharm Biopharm.
  25. , , , , , (). Engineered cell-penetrating peptides for mitochondrion-targeted drug delivery in cancer therapy. Chem Eur J.
  26. , , , , , (). Nanodrug formed by coassembly of dual anticancer drugs to inhibit cancer cell drug resistance. Acs Appl Mater Interfaces.
  27. , , , , , (). Cancer nanomedicines stabilized by pi-pi stacking between heterodimeric prodrugs enable exceptionally high drug loading capacity and safer delivery of drug combinations. Theranostics.
  28. , , , , (). Protein corona:Opportunities and challenges. Int J Biochem Cell Biol.
  29. , , , , (). Protein-excipient interactions:Mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev.
  30. , , , , , (). High-resolution X-ray analysis reveals binding of arginine to aromatic residues of lysozyme surface:implication of suppression of protein aggregation by arginine. Protein Eng Des Sel.
  31. , , , , (). Supramolecular nanostructures formed by anticancer drug assembly. J Am Chem Soc.
  32. , , , , (). Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy. Bba Gen Subjects.
  33. , , , , , (). Self-assembling nanowires of an amphiphilic camptothecin prodrug derived from homologous derivative conjugation. Chem Commun.
  34. , , , , , (). Creation of pure nanodrugs and their anticancer properties. Angew Chem Int Edit.
  35. , (). Pharmacological modulation of mitochondrial calcium homeostasis. J Physiol London.
  36. , , , , , (). Calcium regulates cell death in cancer:Roles of the mitochondria and mitochondria-associated membranes (MAMs). Bba Bioenerget.
  37. , , , , , (). Enzyme-activatable polymer-drug conjugate augments tumour penetration and treatment efficacy. Nat Nanotechnol.
  38. , , , , , (). Acidity-responsive shell-sheddable camptothecin-based nanofibers for carrier-free cancer drug delivery. Nanoscale.
  39. , , , , , (). Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel. Nat Biomed Eng.
  40. , , , , , (). A GSH-responsive nanoprodrug system based on self-assembly of lactose modified camptothecin for targeted drug delivery and combination chemotherapy. Int J Nanomed.
  41. , , (). Carriers for prodrug synthesis:A review. Indian J Pharm Sci.
  42. , , , , , (). A multichannel Ca2+nanomodulator for multilevel mitochondrial destruction-mediated cancer therapy. Adv Mater.
  43. , , , , , (). Oxidative stress mediated Ca2+release manifests endoplasmic reticulum stress leading to unfolded protein response in UV-B irradiated human skin cells. J Dermatol Sci.
  44. , , , , (). Palmitic acid, but not lauric acid, induces metabolic inflammation, mitochondrial fragmentation, and a drop in mitochondrial membrane potential in human primary myotubes. Front Nutr.
  45. , , , , (). Redox and reactive oxygen species regulation of mitochondrial cytochrome c oxidase biogenesis. Antioxid Redox Signal.
  46. , (). The camptothecins. Lancet.
  47. , (). Mitochondria and autophagy:Critical interplay between the two homeostats. Bba Gen Subjects.
  48. , (). Redox regulation of mitochondrial biogenesis. Free Radic Biol Med.
  49. , , (). Redox-mediated regulation of mitochondrial biogenesis, dynamics, and respiratory chain assembly in yeast and human cells. Front Cell Dev Biol.
  50. , , , , , (). MCU-induced mitochondrial calcium uptake promotes mitochondrial biogenesis and colorectal cancer growth. Signal Transduct Tar.
  51. , , , , , (). Helix self-assembly behavior of amino acid-modified camptothecin prodrugs and its antitumor effect. ACS Appl Mater Interfaces.

Conflicts of interest: The authors declare no conflicts of interest.

Funding: This study was supported by the National Natural Science Foundation of China (51922111, 51873208, and 51503200) and the Science and Technology Development Fund, Macau SAR (File no. 0124/2019/A3).